MA34090B1 - Composition pharmaceutique stabilisée - Google Patents

Composition pharmaceutique stabilisée

Info

Publication number
MA34090B1
MA34090B1 MA35251A MA35251A MA34090B1 MA 34090 B1 MA34090 B1 MA 34090B1 MA 35251 A MA35251 A MA 35251A MA 35251 A MA35251 A MA 35251A MA 34090 B1 MA34090 B1 MA 34090B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
stable pharmaceutical
disease
stabilized pharmaceutical
progabalin
Prior art date
Application number
MA35251A
Other languages
Arabic (ar)
English (en)
Inventor
Kamala S Yadav
Amita P Surana
Sanjivani A Kukarni
Rashmi R Prasade
Original Assignee
Egis Gyógyszergyár Nyilvánosan Muködo Részvénytársaság
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyógyszergyár Nyilvánosan Muködo Részvénytársaság filed Critical Egis Gyógyszergyár Nyilvánosan Muködo Részvénytársaság
Publication of MA34090B1 publication Critical patent/MA34090B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE STABILISÉE COMPRENANT DE LA PRÉGABALINE ET UN DISACCHARIDE OU UN POLYLOL SUPÉRIEUR EN TANT QU'AGENT STABILISANT ET ÉVENTUELLEMENT UN EXCIPIENT CLASSIQUE PHARMACEUTIQUEMENT ACCEPTABLE. LA COMPOSITION PHARMACEUTIQUE STABILISÉE SELON L'INVENTION EST UTILE DANS LE TRAITEMENT D'UN CERTAIN NOMBRE DE MALADIES COMME L'ÉPILEPSIE, LA MALADIE D'ALZHEIMER OU LA MALADIE DE PARKINSON.
MA35251A 2010-03-01 2011-03-01 Composition pharmaceutique stabilisée MA34090B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1000120A HU230031B1 (hu) 2010-03-01 2010-03-01 Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
PCT/HU2011/000019 WO2011107812A2 (fr) 2010-03-01 2011-03-01 Composition pharmaceutique stabilisée

Publications (1)

Publication Number Publication Date
MA34090B1 true MA34090B1 (fr) 2013-03-05

Family

ID=89989589

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35251A MA34090B1 (fr) 2010-03-01 2011-03-01 Composition pharmaceutique stabilisée

Country Status (10)

Country Link
US (1) US8968780B2 (fr)
EP (1) EP2542229A2 (fr)
CN (1) CN102869350A (fr)
BR (1) BR112012022255A2 (fr)
EA (1) EA021719B1 (fr)
HU (1) HU230031B1 (fr)
MA (1) MA34090B1 (fr)
UA (1) UA106907C2 (fr)
WO (1) WO2011107812A2 (fr)
ZA (1) ZA201207375B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
WO2019009927A1 (fr) * 2017-07-06 2019-01-10 Adorus Pharmaceuticals Llc Compositions de mélange pour administration orale en tant que poudre et/ou suspension à dissolution rapide
JP6504638B1 (ja) * 2018-05-31 2019-04-24 武田テバファーマ株式会社 錠剤及びその製造方法
CN110613689A (zh) * 2018-06-19 2019-12-27 北京万全德众医药生物技术有限公司 一种含有两亲性聚合物-普瑞巴林复合物的口崩片

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
DE9321600U1 (de) 1993-05-06 2000-04-06 Suedzucker Ag Süssungsmittel
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
AU769038B2 (en) 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
HU228771B1 (en) 1998-05-15 2013-05-28 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
CZ299755B6 (cs) 2001-05-25 2008-11-12 Warner-Lambert Company Llc Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití
WO2003080588A1 (fr) 2002-03-20 2003-10-02 Xenoport Promedicaments 1-(acyloxy)-alkyle cyclique d'analogues de l'acide gamma-aminobutyrique, leurs compositions et leurs utilisations
WO2005051384A1 (fr) 2003-11-25 2005-06-09 Pfizer Limited Compositions pharmaceutiques stabilisees
EP1543831A1 (fr) 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
ITMI20041447A1 (it) 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (fr) 2006-03-17 2007-09-27 Aurobindo Pharma Limited Formulations liquides stables d'agents anti-epileptiques
CN1827590A (zh) * 2006-04-14 2006-09-06 北京润德康医药技术有限公司 一种普瑞巴林新晶型、制备方法及其药用组合物
DE102006030642A1 (de) 2006-07-03 2008-01-10 Conti Temic Microelectronic Gmbh Identifikationssystem
EP2217217B1 (fr) 2007-11-23 2018-05-30 Lupin Limited Compositions pharmaceutiques de prégabaline à libération contrôlée

Also Published As

Publication number Publication date
WO2011107812A2 (fr) 2011-09-09
HU1000120D0 (en) 2010-04-28
ZA201207375B (en) 2014-03-26
CN102869350A (zh) 2013-01-09
WO2011107812A3 (fr) 2011-11-10
BR112012022255A2 (pt) 2016-10-25
UA106907C2 (uk) 2014-10-27
US8968780B2 (en) 2015-03-03
HUP1000120A2 (en) 2011-09-28
HU230031B1 (hu) 2015-05-28
EA201290856A1 (ru) 2013-02-28
EA021719B1 (ru) 2015-08-31
US20130064893A1 (en) 2013-03-14
EP2542229A2 (fr) 2013-01-09

Similar Documents

Publication Publication Date Title
MA34090B1 (fr) Composition pharmaceutique stabilisée
Yu et al. Targeting autophagy in skin diseases
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
Binda et al. Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex
MA33442B1 (fr) Préparations d'insuline contenant de la méthionine
US12006338B2 (en) Antimicrobial organosilanes
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA38289A1 (fr) Composition pharmaceutique à biodisponibilité ameliorée
MA33000B1 (fr) Dicyanopyridine a substitution alkylamino et ses promedicaments d'ester d'acide amine
MX2013006342A (es) Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
BR112014015630A2 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
MA30260B1 (fr) Acides 4-phenyl-thiazole-5-carboxyliques et amides d'acide 4-phenyl-thiazole-5-carboxylique en tant qu'inhibiteurs de plk 1
MA34939B1 (fr) Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MA38646A1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
NZ590885A (en) A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability
TN2011000658A1 (fr) Derives de pyrazoles, leur preparation et leur application en therapeutique
FR3053253B1 (fr) Nouvel extrait d'akenes de silybum marianum et ses utilisations en dermatologie et dermo-cosmetique
MA38307A1 (fr) 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
FR3059236B1 (fr) Extraits de plantes du genre tagetes et leurs utilisations
MA34480B1 (fr) Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires